Evidence map›Paper›PMID 30098269›Full record

Trial reportMovement disorders : official journal of the Movement Disorder Society2018

Low-fat versus ketogenic diet in Parkinson's disease: A pilot randomized controlled trial.

Matthew C L Phillips, Deborah K J Murtagh, Linda J Gilbertson, Fredrik J S Asztely, Christopher D P Lynch

Erratum issued 2 registry-linked trialsOpen access · hybridAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Movement disorders : official journal of the Movement Disorder Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 166 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
166citing papers in PubMed, 7 pooled it
10.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04820478 nacompletednot on this mapstarted 2022, after this paper: background citation

Efficacy and Tolerability of Beta Hydroxybutyrate Ester in Patients With Amyotrophic Lateral Sclerosis (ALS)

TypeinterventionalSponsorUniversity of UlmRan2022 to 2025Enrolled81ConditionsAmyotrophic Lateral SclerosisArmsBeta Hydroxybutyrate Ester (KetoneAid KE4), Placebo
NCT05469997 nacompletednot on this mapstarted 2023, after this paper: background citation

Ketogenic Diet Interventions in Parkinson's Disease: Safeguarding the Gut Microbiome

TypeinterventionalSponsorUniversity of British ColumbiaRan2023 to 2024Enrolled52ConditionsParkinson DiseaseArmsMediterranean-Ketogenic Diet, Mediterranean diet supplemented with medium-chain triglyceride oil
3 · Its place in the literature

Who cites it

166 citing papers in PubMed, 7 syntheses or guidelines pooled it, 278 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Ketogenic diet, cardiometabolic diseases and aging.Journal of geriatric cardiology : JGC · 2026
    Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

106 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Matthew C L PhillipsDepartment of Neurology, Waikato Hospital, Hamilton, New Zealand.
Deborah K J MurtaghHealthy Kitchen Christchurch Ltd, Hamilton, New Zealand.
Linda J GilbertsonDepartment of Neurology, Waikato Hospital, Hamilton, New Zealand.
Fredrik J S AsztelyDepartment of Neurology, Waikato Hospital, Hamilton, New Zealand.
Christopher D P LynchDepartment of Neurology, Waikato Hospital, Hamilton, New Zealand.
Waikato Hospital · NZCanterbury District Health Board · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPreliminary evidence suggests that diet manipulation may influence motor and nonmotor symptoms in PD, but conflict exists regarding the ideal fat to carbohydrate ratio.

objectivesWe designed a pilot randomized, controlled trial to compare the plausibility, safety, and efficacy of a low-fat, high-carbohydrate diet versus a ketogenic diet in a hospital clinic of PD patients.

methodsWe developed a protocol to support PD patients in a diet study and randomly assigned patients to a low-fat or ketogenic diet. Primary outcomes were within- and between-group changes in MDS-UPDRS Parts 1 to 4 over 8 weeks.

resultsWe randomized 47 patients, of which 44 commenced the diets and 38 completed the study (86% completion rate for patients commencing the diets). The ketogenic diet group maintained physiological ketosis. Both groups significantly decreased their MDS-UPDRS scores, but the ketogenic group decreased more in Part 1 (-4.58 ± 2.17 points, representing a 41% improvement in baseline Part 1 scores) compared to the low-fat group (-0.99 ± 3.63 points, representing an 11% improvement) (P < 0.001), with the largest between-group decreases observed for urinary problems, pain and other sensations, fatigue, daytime sleepiness, and cognitive impairment. There were no between-group differences in the magnitude of decrease for Parts 2 to 4. The most common adverse effects were excessive hunger in the low-fat group and intermittent exacerbation of the PD tremor and/or rigidity in the ketogenic group.

conclusionsIt is plausible and safe for PD patients to maintain a low-fat or ketogenic diet for 8 weeks. Both diet groups significantly improved in motor and nonmotor symptoms; however, the ketogenic group showed greater improvements in nonmotor symptoms. © 2018 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

Indexed as

AdultAgedBlood GlucoseDiet, Fat-RestrictedDiet, KetogenicFemaleFollow-Up StudiesHumansKetonesMaleMiddle AgedNeuropsychological TestsOutcome Assessment, Health CareParkinson DiseasePilot ProjectsSeverity of Illness IndexBlood GlucoseKetonesketogenic dietlow-fat dietMDS-UPDRSParkinson's disease

Identifiers

PMID30098269
PMCPMC6175383
OpenAlexW2887866827

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.